Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [3406]
News [7771]
Articles [63]
Editorials [9]
Conferences [207]
elearning [49]
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma
Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany
FDG-PET guidance allows substantial chemoreduction in Hodgkin lymphoma ( Dr Peter Borchmann - Uniklinik Koeln, Cologne, Germany )
24 Jun 2017
ZUMA 1: CD19 CAR T cells for refractory NHL
Dr Yi Lin, Mayo Clinic - Rochester, MN, USA
ZUMA 1: CD19 CAR T cells for refractory NHL ( Dr Yi Lin, Mayo Clinic - Rochester, MN, USA )
24 Jun 2017
Risk and benefit of anti-coagulants for elderly patients with cancer-associated...
Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London...
Risk and benefit of anti-coagulants for elderly patients with cancer-associated venous thromboembolism ( Dr Alejandro Lazo-Langner - Department of Medicine, Western University, London, Ontario, Canada )
24 Jun 2017
400mg imatinib as good as 800mg for 10 year CML survival
Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany
400mg imatinib as good as 800mg for 10 year CML survival ( Prof Rüdiger Hehlmann - European LeukemiaNet, Mannheim, Germany )
23 Jun 2017
Carfilzomib combinations in ENDEAVOR and FORTE
Prof Katja Weisel - University of Tübingen, Tübingen, Germany
Carfilzomib combinations in ENDEAVOR and FORTE ( Prof Katja Weisel - University of Tübingen, Tübingen, Germany )
23 Jun 2017
Deep molecular response to gilteritinib in CHRYSALIS trial
Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern...
Deep molecular response to gilteritinib in CHRYSALIS trial ( Dr Jessica Altman - Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, USA )
23 Jun 2017
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Dual JAK/SYK inhibition in refractory NHL with cerdulatinib ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed...
Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA
Cerdulatinib demonstrates rapid responses in a phase 2 study for relapsed/refractory NHL ( Dr Paul Hamlin - Memorial Sloan Kettering Cancer Center, NY, USA )
23 Jun 2017
Improving outcomes for oestrogen receptor positive breast cancer
Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy
Improving outcomes for oestrogen receptor positive breast cancer ( Dr Giancarlo Pruneri - European Institute of Oncology, Milan, Italy )
19 Jun 2017
European guidelines for breast cancer treatment
Dr Ciarán Nicholl - Research Centre Ispra, European Commission, Belgium
European guidelines for breast cancer treatment ( Dr Ciarán Nicholl - Research Centre Ispra, European Commission, Belgium )
19 Jun 2017
ESMO ranking of the clinical benefits of new drugs
Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy
ESMO ranking of the clinical benefits of new drugs ( Prof Alberto Sobrero - Ospedale San Martino, Genova, Italy )
19 Jun 2017
The recent past and near future of drug approvals in Europe
Prof Filippo de Braud - Istituto Nazionale dei Tumori, Milan, Italy
The recent past and near future of drug approvals in Europe ( Prof Filippo de Braud - Istituto Nazionale dei Tumori, Milan, Italy )
19 Jun 2017

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation